Rituximab treatment demonstrated a significant reduction in IL-17 expression in the salivary glands of SS patients, while factors that are important for maintenance of Th17 cells, as STAT3 and IL-23, are likely not affected (228). Here, IL23A is linked to synovial sarcoma.